139 related articles for article (PubMed ID: 36513192)
1. Potential target identification for osteosarcoma treatment: Gene expression re-analysis and drug repurposing.
Kamolphiwong R; Kanokwiroon K; Wongrin W; Chaiyawat P; Klangjorhor J; Settakorn J; Teeyakasem P; Sangphukieo A; Pruksakorn D
Gene; 2023 Mar; 856():147106. PubMed ID: 36513192
[TBL] [Abstract][Full Text] [Related]
2. New drug candidates for osteosarcoma: Drug repurposing based on gene expression signature.
Andrade RC; Boroni M; Amazonas MK; Vargas FR
Comput Biol Med; 2021 Jul; 134():104470. PubMed ID: 34004576
[TBL] [Abstract][Full Text] [Related]
3. Truly Man's Best Friend: Canine Cancers Drive Drug Repurposing in Osteosarcoma.
Weiss MC; Eulo V; Van Tine BA
Clin Cancer Res; 2022 Feb; 28(4):571-572. PubMed ID: 34880110
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Analysis of Key mRNAs and lncRNAs in Osteosarcoma Response to Preoperative Chemotherapy with Prognostic Values.
Li M; Cheng WT; Li H; Zhang Z; Lu XL; Deng SS; Li J; Yang CH
Curr Med Sci; 2021 Oct; 41(5):916-929. PubMed ID: 34671904
[TBL] [Abstract][Full Text] [Related]
5. The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal Pathways.
Liao Z; Nan G; Yan Z; Zeng L; Deng Y; Ye J; Zhang Z; Qiao M; Li R; Denduluri S; Wang J; Wei Q; Geng N; Zhao L; Lu S; Wang X; Zhou G; Luu HH; Haydon RC; He TC; Wang Z
Curr Cancer Drug Targets; 2015; 15(8):726-38. PubMed ID: 26118906
[TBL] [Abstract][Full Text] [Related]
6. Identification of the Novel Target Genes for Osteosarcoma Therapy Based on Comprehensive Bioinformatic Analysis.
Zhou X; Fan Y; Ye W; Jia B; Yang Y; Liu Y
DNA Cell Biol; 2020 Jul; 39(7):1172-1180. PubMed ID: 32584170
[TBL] [Abstract][Full Text] [Related]
7. Identification of PSMD14 as a potential novel prognosis biomarker and therapeutic target for osteosarcoma.
Gong Y; Wei ZR
Cancer Rep (Hoboken); 2022 Jul; 5(7):e1522. PubMed ID: 34383385
[TBL] [Abstract][Full Text] [Related]
8. Identification of key genes in osteosarcoma - before and after CDK7 treatment.
An Y; Wang Y; Xu G; Liao Y; Huang G; Jin X; Xie C; Li Q; Yin D
Medicine (Baltimore); 2021 Oct; 100(39):e27304. PubMed ID: 34596127
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide.
Bruheim S; Xi Y; Ju J; Fodstad O
Clin Cancer Res; 2009 Dec; 15(23):7161-9. PubMed ID: 19920113
[TBL] [Abstract][Full Text] [Related]
10. Identification of potential crucial genes associated with vasculogenic mimicry in human osteosarcoma based on gene expression profile.
Yao N; Ren K; Gu XJ; Wu SJ; Shi X; Chang Q; Li YG; Gao ZX; Jin QM; Zhang J; Wang C; Zhou J
Neoplasma; 2020 Mar; 67(2):286-295. PubMed ID: 31884799
[TBL] [Abstract][Full Text] [Related]
11. Identification of potential crucial genes and key pathways in osteosarcoma.
Liu J; Wu S; Xie X; Wang Z; Lei Q
Hereditas; 2020 Jul; 157(1):29. PubMed ID: 32665038
[TBL] [Abstract][Full Text] [Related]
12. Identification of hub genes specific to pulmonary metastasis in osteosarcoma through integrated bioinformatics analysis.
Chai Y; Xu L; He R; Zhong L; Wang Y
Technol Health Care; 2022; 30(3):735-745. PubMed ID: 34542049
[TBL] [Abstract][Full Text] [Related]
13. [Data-driven drug discovery for drug repurposing].
Saito R; Yano N; Kojima S; Miyoshi F
Nihon Yakurigaku Zasshi; 2023; 158(1):10-14. PubMed ID: 36596476
[TBL] [Abstract][Full Text] [Related]
14. The genetic basis for inactivation of Wnt pathway in human osteosarcoma.
Du X; Yang J; Yang D; Tian W; Zhu Z
BMC Cancer; 2014 Jun; 14():450. PubMed ID: 24942472
[TBL] [Abstract][Full Text] [Related]
15. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
[TBL] [Abstract][Full Text] [Related]
16. Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures.
Pizzorno A; Terrier O; Nicolas de Lamballerie C; Julien T; Padey B; Traversier A; Roche M; Hamelin ME; Rhéaume C; Croze S; Escuret V; Poissy J; Lina B; Legras-Lachuer C; Textoris J; Boivin G; Rosa-Calatrava M
Front Immunol; 2019; 10():60. PubMed ID: 30761132
[TBL] [Abstract][Full Text] [Related]
17. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents.
Buddingh EP; Kuijjer ML; Duim RA; Bürger H; Agelopoulos K; Myklebost O; Serra M; Mertens F; Hogendoorn PC; Lankester AC; Cleton-Jansen AM
Clin Cancer Res; 2011 Apr; 17(8):2110-9. PubMed ID: 21372215
[TBL] [Abstract][Full Text] [Related]
18. CDK4 overexpression is a predictive biomarker for resistance to conventional chemotherapy in patients with osteosarcoma.
Iwata S; Tatsumi Y; Yonemoto T; Araki A; Itami M; Kamoda H; Tsukanishi T; Hagiwara Y; Kinoshita H; Ishii T; Nagase H; Ohira M
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34036394
[TBL] [Abstract][Full Text] [Related]
19. 12 Survival-related differentially expressed genes based on the TARGET-osteosarcoma database.
Rothzerg E; Xu J; Wood D; Kõks S
Exp Biol Med (Maywood); 2021 Oct; 246(19):2072-2081. PubMed ID: 33926256
[TBL] [Abstract][Full Text] [Related]
20. Anoikis-resistant subpopulations of human osteosarcoma display significant chemoresistance and are sensitive to targeted epigenetic therapies predicted by expression profiling.
Foley JM; Scholten DJ; Monks NR; Cherba D; Monsma DJ; Davidson P; Dylewski D; Dykema K; Winn ME; Steensma MR
J Transl Med; 2015 Apr; 13():110. PubMed ID: 25889105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
